-
Posted by
Two Blokes Jul 21 -
Filed in
Stock
-
8 views
NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based biotech firm reported increased survival in mice infected with a lethal dose of the measles virus by 130%, extending average survival time to 17 days compared to 7.4 days in untreated animals.
